Together our observations suggest that PIs might be a therapeutic option for endocrine resistant ER+ breast cancer patients, independently of whether endocrine resistance is mediated by deregulated growth factor receptor signaling or by ERα mutations. Here, ESR1 is linked to breast carcinoma.